Interaction of Synthetic Human SLURP-1 with the Nicotinic Acetylcholine Receptors by Durek, Thomas et al.
University of Wollongong
Research Online
Illawarra Health and Medical Research Institute Faculty of Science, Medicine and Health
2017





Russian Academy of Sciences
Han Shen Tae




Russian Academy of Sciences
See next page for additional authors
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Durek, T., Shelukhina, I. V., Tae, H., Thongyoo, P., Spirova, E. N., Kudryavtsev, D. S., Kasheverov, I. E., Faure, G., Corringer, P., Craik,
D. J., Adams, D. J. & Tsetlin, V. I. (2017). Interaction of Synthetic Human SLURP-1 with the Nicotinic Acetylcholine Receptors.
Scientific Reports, 7 16606-1-16606-11.
Interaction of Synthetic Human SLURP-1 with the Nicotinic
Acetylcholine Receptors
Abstract
Human SLURP-1 is a secreted protein of the Ly6/uPAR/three-finger neurotoxin family that co-localizes with
nicotinic acetylcholine receptors (nAChRs) and modulates their functions. Conflicting biological activities of
SLURP-1 at various nAChR subtypes have been based on heterologously produced SLURP-1 containing N-
and/or C-terminal extensions. Here, we report the chemical synthesis of the 81 amino acid residue human
SLURP-1 protein, characterization of its 3D structure by NMR, and its biological activity at nAChR subtypes.
Radioligand assays indicated that synthetic SLURP-1 did not compete with [125I]-α-bungarotoxin (α-Bgt)
binding to human neuronal α7 and Torpedo californica muscle-type nAChRs, nor to mollusk acetylcholine
binding proteins (AChBP). Inhibition of human α7-mediated currents only occurred in the presence of the
allosteric modulator PNU120596. In contrast, we observed robust SLURP-1 mediated inhibition of human
α3β4, α4β4, α3β2 nAChRs, as well as human and rat α9α10 nAChRs. SLURP-1 inhibition of α9α10 nAChRs
was accentuated at higher ACh concentrations, indicating an allosteric binding mechanism. Our results are
discussed in the context of recent studies on heterologously produced SLURP-1 and indicate that N-terminal
extensions of SLURP-1 may affect its activity and selectivity on its targets. In this respect, synthetic SLURP-1
appears to be a better probe for structure-function studies.
Disciplines
Medicine and Health Sciences
Publication Details
Durek, T., Shelukhina, I. V., Tae, H., Thongyoo, P., Spirova, E. N., Kudryavtsev, D. S., Kasheverov, I. E., Faure,
G., Corringer, P., Craik, D. J., Adams, D. J. & Tsetlin, V. I. (2017). Interaction of Synthetic Human SLURP-1
with the Nicotinic Acetylcholine Receptors. Scientific Reports, 7 16606-1-16606-11.
Authors
Thomas Durek, Irina V. Shelukhina, Han Shen Tae, Panumart Thongyoo, Ekaterina N. Spirova, Denis S.
Kudryavtsev, Igor E. Kasheverov, Grazyna Faure, Pierre-Jean Corringer, David J. Craik, David J. Adams, and
Victor I. Tsetlin
This journal article is available at Research Online: http://ro.uow.edu.au/ihmri/1191
1Scientific REPoRTS | 7: 16606  | DOI:10.1038/s41598-017-16809-0
www.nature.com/scientificreports
Interaction of Synthetic Human 
SLURP-1 with the Nicotinic 
Acetylcholine Receptors
Thomas Durek  1, Irina V. Shelukhina2, Han-Shen Tae 3, Panumart Thongyoo1,5, Ekaterina 
N. Spirova2, Denis S. Kudryavtsev  2, Igor E. Kasheverov2, Grazyna Faure4, Pierre-Jean 
Corringer4, David J. Craik  1, David J. Adams  3 & Victor I. Tsetlin2
Human SLURP-1 is a secreted protein of the Ly6/uPAR/three-finger neurotoxin family that co-localizes 
with nicotinic acetylcholine receptors (nAChRs) and modulates their functions. Conflicting biological 
activities of SLURP-1 at various nAChR subtypes have been based on heterologously produced SLURP-1 
containing N- and/or C-terminal extensions. Here, we report the chemical synthesis of the 81 amino 
acid residue human SLURP-1 protein, characterization of its 3D structure by NMR, and its biological 
activity at nAChR subtypes. Radioligand assays indicated that synthetic SLURP-1 did not compete 
with [125I]-α-bungarotoxin (α-Bgt) binding to human neuronal α7 and Torpedo californica muscle-type 
nAChRs, nor to mollusk acetylcholine binding proteins (AChBP). Inhibition of human α7-mediated 
currents only occurred in the presence of the allosteric modulator PNU120596. In contrast, we observed 
robust SLURP-1 mediated inhibition of human α3β4, α4β4, α3β2 nAChRs, as well as human and rat 
α9α10 nAChRs. SLURP-1 inhibition of α9α10 nAChRs was accentuated at higher ACh concentrations, 
indicating an allosteric binding mechanism. Our results are discussed in the context of recent studies on 
heterologously produced SLURP-1 and indicate that N-terminal extensions of SLURP-1 may affect its 
activity and selectivity on its targets. In this respect, synthetic SLURP-1 appears to be a better probe for 
structure-function studies.
The three-finger fold is a protein domain structure comprising a disulfide-stabilized core from which three elon-
gated loops (fingers) protrude (Fig. 1). It features prominently in two large protein families: snake venom neu-
rotoxins and the Ly6 proteins, the latter first discovered in the mammalian immune system1–4. Besides their 
similar 3D structures, proteins with this fold also share a similar genetic organization and a conserved pattern 
and connectivity of cysteine residues that ultimately form the structure-stabilizing disulfides. These common 
features provide strong evidence that Ly6 proteins and snake venom neurotoxins are evolutionary related, how-
ever, despite the structural similarities the functional link between these two families has only emerged recently.
Most Ly6 proteins are membrane-tethered by a covalently attached glycosyl phosphatidylinositol (GPI) 
anchor, such as for Ly6/neurotoxin 1 (Lynx1), but some are secreted proteins including SLURP-1 (secreted 
Ly6/urokinase-type plasminogen receptor-related protein), which was initially isolated from human blood 
and urine5. SLURP-1 is also expressed in keratinocytes and SLURP-1 mutations are implicated in the Mal de 
Meleda skin disease4,6. Additionally, SLURP-1 has been reported to regulate processes in the immune and nervous 
systems7–9.
SLURP-1 (as well as other Ly6 proteins such as Lynx1 and SLURP-2) represents a functional link between the 
mammalian Ly6 proteins and snake neurotoxins. Many members from the latter group, which include the well 
characterized pharmacological agents α-bungarotoxin (α-Bgt) and α-cobratoxin (α-Cbt), are potent inhibitors 
of nicotinic acetylcholine receptors (nAChR). Co-localization studies and functional in vitro activity data have 
demonstrated that certain Ly6 proteins (Lynx1 and SLURP-1 and -2) also interact with nAChRs, suggesting that 
they might function as endogenous modulators of nAChR signaling in vivo10,11.
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Various recombinant versions of SLURP-1 have been shown to modulate nAChRs, mostly of the α7 sub-
type7,8,12, but with contradictory results due to the expressed SLURP-1 proteins containing additional C- or 
N-terminal fusion tags. For example, Chimienti and colleagues reported potentiation of α7 nAChR-mediated 
currents by a recombinant myc-His6-SLURP-1 fusion construct at low nanomolar concentrations12. In contrast, 
recombinant SLURP-1 expressed in E. coli, containing an additional methionine residue at the N-terminus (here-
after referred to as rSLURP-1), exhibited inhibitory activity at α7 nAChR (at micromolar concentrations)13.
To resolve these conflicting data on SLURP-1 activities, we report here the chemical synthesis and biological 
activity of the 81 amino acid human SLURP-1 identical in amino acid sequence to the human serum-derived 
protein. Using a combination of solid phase peptide synthesis and native chemical ligation14, high purity protein 
was obtained in multi-milligram amounts sufficient for structural and functional studies. The synthetic protein 
was characterized by HPLC, MS, and NMR which confirmed the three-finger fold structure. Most importantly, 
our pharmacological data revealed for the first time the interaction of synthetic SLURP-1 (sSLURP-1) with several 
neuronal nAChR subtypes.
Results
Human SLURP-1 synthesis and NMR structural analysis. Human SLURP-1, with 81 amino acid res-
idues and five disulfide bonds, is considerably larger than most three-finger proteins from snake venoms (up to 
62 residues and four disulfides). It is reminiscent of the classical long-chain α-neurotoxins, which are typically 
composed of up to 75 residues with a 5th disulfide bond in the central loop II. In contrast, in all Ly6 proteins, 
including SLURP-1, the 5th disulfide resides in the N-terminal loop I4. Given the size of the target SLURP-1 mol-
ecule, we resorted to a peptide segment ligation approach to overcome the size limitation of traditional stepwise 
solid phase peptide synthesis (SPPS) (Figs 1 and 2)15. Accordingly, the SLURP-1 polypeptide chain was split into 
three segments, which were individually assembled by either Boc or Fmoc SPPS (see Materials and Methods). 
Thiazolidine-4-carboxylic acid (Thz) was used in place of Cys2116,17 to prevent cyclisation and oligomerisation 
during the first chemical ligation of SLURP-1[21–50] and SLURP-1[51–81]. Following cleavage from the solid 
support and purification, the segments were joined via native chemical ligation in one-pot fashion as described 
previously16,18.
The fully reduced SLURP-1 polypeptide was obtained in good yield (69% based on the limiting starting pep-
tide segment SLURP-1[51–81]). Folding and disulfide formation of the synthetic molecule was achieved using 
protocols described recently for inclusion body refolding of rSLURP-1 produced in E. coli13,19. The folding kinet-
ics and the overall HPLC folding profile were essentially identical to those reported for rSLURP-1 and allowed 
preparation of synthetic SLURP-1 in high purity and in multi-milligram quantities (Fig. 2D–F). High resolution 
MS analysis indicated a monoisotopic mass of 8837.1 ± 0.1 Da, in excellent agreement with the theoretical monoi-
sotopic mass of 8837.02 Da demonstrating formation of five disulfide bonds (Fig. 2F).
To verify the anticipated three-finger fold of the synthetic material, we performed NMR experiments under 
the same conditions as reported previously for rSLURP-1 (i.e., H2O/D2O (9:1), pH 4.8, 310 K)19. The natural abun-
dance 1H-15N HSQC spectrum of SLURP-1 showed good dispersion of amide proton and nitrogen resonances 
(Fig. 3A) suggesting that the molecule adopts a well-defined three-dimensional structure. Overall, the spectrum 
is highly similar to that of rSLURP-119. Two-dimensional TOCSY and NOESY spectra were used to assign back-
bone amide and CαH protons. Comparison of the Hα chemical shift of each residue obtained from synthetic 
SLURP-1 spectra to the values available for rSLURP-1 (BMRB ID: 25225 and 25226; Fig. 3B) revealed excellent 
agreement, suggesting the proteins have highly similar three-dimensional structures. This suggestion is further 
supported by several key long-range NOEs observed in the NOESY spectra of synthetic SLURP-1, including 
Lys2Hα-Arg20Hα, Cys28Hα-Cys51Hα, Met29Hα-Cys71Hα, Thr30Hα-Arg49Hα and Leu76Hα-Tyr4Hδ/ε, all 
Figure 1. Chemical synthesis of SLURP-1 via one-pot native chemical ligation (NCL). (a) NCL, (b) Thz to 
Cys conversion and (c) folding and disulfide bond formation. The primary structure and sequence5 of human 
SLURP-1 are shown at the bottom. The two cysteines that were used as ligation sites are highlighted.
www.nature.com/scientificreports/
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consistent with the proposed three-finger fold. Taken together, these data confirm that our synthetic SLURP-1 has 
a tertiary structure similar to that of rSLURP-1.
Human SLURP-1 does not compete with α-Bgt at human neuronal α7, muscle-type nAChRs 
and AChBPs. The recombinant form of SLURP-1 was shown previously to displace bound α-Bgt from the 
muscle-type nAChR of Torpedo californica and the mollusk Lymnaea stagnalis AChBP13. However, in the pres-
ent study, the synthetic version of SLURP-1 did not compete with α-Bgt for either proteins (Fig. 4). In addition, 
no competition with α-Bgt binding was observed at either human (h) α7 nAChR or Aplysia californica AChBP 
(Fig. 4).
SLURP-1 inhibition of hα7 nAChR in the presence of the positive allosteric modulator PNU120596. 
In the [125I]-α-Bgt binding assay, synthetic SLURP-1 showed no competitive antagonism at hα7 nAChR, consist-
ent with the reported inactivity of rSLURP-1 in the same assay13. However, rSLURP-1 inhibited ACh-evoked cur-
rents at hα7 nAChR13 and since the inhibition showed a direct relationship with the ACh concentration, we tested 
synthetic SLURP-1 at hα7 and rat (r) α7 nAChRs heterologously expressed in Xenopus laevis oocytes, under 
similar conditions (Fig. 5). At 10 μM, regardless of the ACh concentrations used (10, 100, 300, or 1000 µM), syn-
thetic SLURP-1 did not antagonize ACh-evoked currents mediated by hα7 (Fig. 5A,B) and rα7 (Fig. 5A and C) 
nAChR subtypes.
The activity of some ligands at α7 nAChR-mediated currents can be amplified in the presence of the α7 sub-
type specific positive allosteric modulator PNU12059620. Therefore, we investigated the activity of sSLURP-1 in 
the presence of 10 μM PNU120596 and indeed, inhibition of epibatidine (Epi)-induced Ca2+ influx (59% inhi-
bition by 5 μM SLURP-1 at 150 nM Epi) was observed in neuroblastoma Neuro2a cells expressing hα7 nAChR 
(Fig. 5D). sSLURP-1 was also tested on mouse muscle nAChRs expressed in Neuro2a cells but no significant 
inhibition of ACh-evoked Ca2+ influx was detected (Suppl. Figure 1).
Figure 2. Monitoring chemical synthesis of SLURP-1 by uHPLC. (A-C) One-pot NCL of SLURP-1 segments. 
(A) Ligation of SLURP-1[21–50] and SLURP-1[51–81]-α-thioester segments at t = 0 and, (B) after 12 h ligation 
and Thz to Cys conversion. (C) SLURP-1[1–20]-α-thioester segment was subsequently added and ligated 
to fragment 21–81 to form the reduced SLURP-1 polypeptide. (D,E) Folding of the SLURP-1 polypeptide 
monitored by uHPLC. (D) Reduced SLURP-1 and (E) crude folding mixture after 70 h. The principal peak at 
retention time 5 min corresponds to correctly folded human SLURP-1. ESI-MS spectra of the dominant peaks 
are shown as inserts. (F) uHPLC and high-resolution MS analysis of purified human sSLURP-1. The inset shows 
an isotopically resolved blow-up of the [M + 7 H]7+ charge state.
www.nature.com/scientificreports/
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Selective inhibition of heteromeric human neuronal nAChRs by SLURP-1. The activity of 
sSLURP-1 was also determined at respective ACh EC50 currents of heteromeric human nAChRs expressed in X. 
laevis oocytes (Fig. 6). sSLURP-1 at 10 µM reversibly inhibited ACh-evoked current amplitude of hα3β4 nAChRs 
by ~60%, whereas ~30% inhibition was observed at hα3β2 and hα4β4 nAChRs, and no inhibition was observed 
Figure 3. NMR characterization of synthetic human SLURP-1. (A) 1H-15N HSQC spectrum of synthetic 
SLURP-1 (H2O/D2O (9:1), pH 4.8, 310 K) and (B) Hα chemical shift comparison of synthetic SLURP-1 and 
rSLURP-1 (BMRB 25225, PDB ID: 2MUO).
Figure 4. Synthetic SLURP-1 activity at the orthosteric site of human α7 nAChR expressed in GH4C1 cells, 
muscle-type nAChR of T. californica (Tca), and AChBPs from A. californica (Aca) and L. stagnalis (Lst). Binding 
was assessed in competition with [125I]-α-Bgt (0.2 nM). Each data point represents the mean ± SEM of 3 
independent experiments.
www.nature.com/scientificreports/
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at hα4β2 nAChR. sSLURP-1 inhibited ACh-evoked currents mediated by hα3β4 in a concentration-dependent 
manner with an IC50 of 4.75 ± 0.78 µM (Fig. 6D). At hα3β4 nAChR in the presence of <300 µM ACh (EC50), 
sSLUPR-1 inhibition was enhanced (~80% with both 30 and 100 µM ACh), whereas with 1 mM ACh, sSLURP-1 
inhibitory effect was comparable to that observed with 300 µM ACh. Interestingly, although the hα9α10 sub-
type was not inhibited by sSLURP-1 in the presence of 6 μM ACh (EC50), sSLURP-1 inhibition became clearly 
manifested at 100 and 300 μM ACh (~25% and ~40% inhibition of ACh-evoked current amplitude, respectively) 
(Fig. 6A and B). Furthermore, we also demonstrated the sensitivity of rα9α10 nAChR to sSLURP-1 inhibition 
which strongly correlated with the increased concentration of agonist (Fig. 6A and C).
Discussion
Human SLURP-1 has the canonical three-finger folded structure of the snake α-neurotoxins, which are known as 
potent antagonists of nAChRs4. SLURP-1 has been shown to participate in a number of cellular regulation path-
ways, supposedly by acting on the homomeric α7 nAChR subtype6–9,21,22. However, the mechanism of interaction 
between SLURP-1 and α7 nAChR remains unclear due to the disparities in the activities of the recombinant 
human SLURP-1 constructs used. Recently, it was demonstrated that rSLURP-1 inhibited α7 nAChR-mediated 
currents13, whereas potentiation was reported previously for the myc-tagged fusion protein12. In contrast, binding 
of rSLURP-1 at the orthosteric and allosteric sites of different targets was registered13, which is in agreement with 
the similar activity of ws-Lynx1, thus supporting the proposed binding models23,24. We suspected these discrep-
ancies potentially originate from the different chemical structures of the various recombinant forms of SLURP-1 
used. Hence to resolve the conflicting data, we chemically synthesized the SLURP-1 protein (sSLURP-1) identical 
in amino acid sequence to the naturally-occurring human molecule5, and determined its structural and biological 
properties.
Three-finger proteins have been obtained previously by stepwise chemical solid phase peptide synthe-
sis (SPPS)25. However, to the best of our knowledge, this approach has been limited to selected short-chain 
Figure 5. Activity of synthetic SLURP-1 on agonist-evoked response mediated by α7 nAChRs. (A) 
Representative ACh-evoked current traces through hα7 and rα7 nAChRs in the presence of 10 µM sSLURP-1. 
(B) Bar graph of sSLURP-1 activity (10 μM) on ACh-evoked peak current amplitude mediated by hα7 and (C) 
rα7 nAChRs expressed in X. laevis oocytes. (D) Concentration-response curve of epibatidine (Epi) + 10 µM 
PNU120596-induced intracellular calcium ion concentration ([Ca2+]i) rise in Neuro2a cells expressing hα7 
nAChRs in the absence (black squares, EC50 = 44.9 ± 4.6 nM) and presence of 5 µM sSLURP-1 (open circles). 
Mean ± SEM, n = 3–10. *P < 0.05 vs [Ca2+]i rise evoked by corresponding agonist concentration in the absence 
of sSLURP-1, unpaired two-tailed Student’s t-test.
www.nature.com/scientificreports/
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α-neurotoxins typically comprising ~60 amino acids and four disulfide bonds, with the longest being the syn-
thetic non-conventional neurotoxin, built of 66 residues with five disulfides26. Larger proteins, including SLURP-
1, are generally difficult to synthesize by stepwise Fmoc or Boc SPPS alone15.
Chemical synthesis of SLURP-1 was achieved using a convergent approach whereby the polypeptide was 
divided initially into three shorter peptide segments, each ranging in size of about 20–30 amino acids. The 
segments were prepared by Boc or Fmoc SPPS in good yield and purity, purified individually by HPLC and 
chemo-selectively linked together using the recently established one-pot native chemical ligation protocol16. 
Folding and disulfide bond formation of the synthetic 81-mer was achieved over 72 h using a glutathione redox 
shuffling system. To our knowledge, the successful chemical synthesis of SLURP-1 reported here, is the first exam-
ple of a long chain three-finger protein of the Ly6 family obtained solely through chemical synthesis.
To unambiguously confirm the anticipated 3D structure, we performed NMR experiments that allowed 
near-complete assignment of backbone NH and CαH protons (as well as partial side chain proton assignments). 
This analysis and comparison with data previously obtained for rSLURP-119, established that the synthetic mole-
cule is structurally highly comparable to the recombinant protein.
Contrary to earlier reports of various recombinant SLURP-1 versions interacting with AChBPs and 
nAChRs6–9,19,21, we did not observe competition of synthetic SLURP-1 with radio-iodinated α-Bgt for binding to 
AChBPs of L. stagnalis and A. californica, nor to muscle-type T. californica nAChR (Fig. 4). Interestingly, although 
neither synthetic SLURP-1 and rSLURP-1 did compete with α-Bgt binding to hα7 nAChR, only rSLURP-1 inhib-
ited ACh-evoked currents at hα7 nAChR with an IC50 of ~1 μM and the inhibition was enhanced with increasing 
ACh concentrations13. However, synthetic SLURP-1 did not inhibit either hα7 or rα7 nAChRs in the presence 
of low and high concentrations of ACh (Fig. 5A–C). The antagonistic effect of sSLURP-1 was only observed 
under the influence of the α7 nAChR positive allosteric modulator PNU120596, where substantial inhibition of 
hα7-mediated epibatidine-induced Ca2+ influx (Fig. 5D) was observed.
Screening of sSLURP-1 at 10 μM against a number of heteromeric human neuronal nAChR subtypes, demon-
strated preferential inhibition of nAChRs co-expressing α3 and β4 subunits (Fig. 6A and B), with hα3β4 nAChR 
being more sensitive to inhibition by sSLURP-1 compared to hα3β2 and α4β4 nAChRs. This finding suggests 
that the binding site of sSLURP-1 might be located at the interface of α3 and β4 subunits and sSLURP-1 behaved 
as a competitive antagonist of the hα3β4 subtype. On the other hand, both hα9α10 (Fig. 6A and B) and rα9α10 
(Fig. 6A and C) nAChRs showed ACh-dependent sSLURP-1 inhibition, with sSLURP-1 exerting its action at 
relatively high ACh concentrations. Ws-Lynx1 (a recombinant version of Lynx1 lacking the GPI anchor) was 
also shown to profoundly inhibit hα7, α3β2, and α4β2 nAChRs23, and the chimeric α7/glycine (Gly) receptor24 
in similar fashion.
Figure 6. Activity of synthetic SLURP-1 on heteromeric human and rat neuronal nAChRs. (A) Representative 
ACh-evoked current traces mediated by hα3β4, hα4β2, hα9α10 and rα9α10 nAChRs in the presence of 10 µM 
sSLURP-1. (B) Bar graph of sSLURP-1 (10 μM) inhibition of ACh (EC50)-evoked current mediated by hα3β2 
(6 µM), α3β4 (300 µM), α4β2 (3 µM), α4β4 (6 µM) and α9α10 (6 µM) nAChRs and with ACh concentrations 
below or above the EC50 for hα3β4 (30, 100 and 1000 µM) and α9α10 (100 and 300 µM). Whole-cell currents 
were activated by the ACh concentrations indicated. (C) Bar graph of 10 µM sSLURP-1 inhibition of ACh-
evoked peak current amplitude mediated by rα9α10 nAChR. ACh concentrations tested were from 10 to 
100 µM (ACh EC50 for rα9α10 receptor was 20 μM). Mean ± SEM, n = 6–14. *P < 0.05, **P < 0.0001 vs 
relative current amplitude in the absence of sSLURP-1, unpaired two-tailed Student’s t-test. (D) Concentration- 
response curve of sSLURP-1 inhibition of 300 µM ACh-evoked current amplitude mediated by hα3β4 nAChRs. 
Mean ± SEM, n = 3–10.
www.nature.com/scientificreports/
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Overall, sSLURP-1 inhibition at the human αβ (except hα4β2) and α9α10 nAChRs subtypes can be registered 
at low ([ACh] ~EC50) and high ACh concentrations, respectively, conditions that are more “physiologically rel-
evant”. In contrast, the action of sSLURP-1 on the hα7 nAChR is observed only in the presence of the artificial 
potentiator PNU120596.
Taken together, the results obtained for α7 and α9α10 nAChRs suggest that sSLURP-1 behaves as a ‘silent’ 
negative allosteric modulator, exerting its inhibitory effect at the nAChRs only when the receptor channels 
are in a stable open state. A similar unmasking effect on ligand activity was also reported for α-conotoxin 
MrIC27 and the marine sponge-derived 6-bromohypaphorine28, where both behave as an agonist by eliciting 
concentration-dependent increases in [Ca2+]i via PNU120596-modified hα7 nAChR.
As for α9α10, the mode of action of sSLURP-1 on this nAChR subtype mirrors the proposed negative 
allosteric mechanism of rSLURP-113 and ws-Lynx123,24 where both are more potent inhibitors of α7 nAChR in the 
presence of high ACh concentrations. Despite the structural similarities in the NMR-Hα chemical shift profiles 
of sSLURP-1 and rSLURP-1 (Fig. 3B), these proteins clearly behave differently at their targets.
Using the published NMR structure of rSLURP-1 (PDB ID: 2MUO), we built a model for sSLURP-1 (Fig. 7A) 
to investigate in more detail the structural differences between the two proteins. Molecular dynamic simulation 
of both structures indicates that the additional N-terminal methionine (Met0) residue in the rSLURP-1 is tightly 
packed inside the disulfide-rich core of the molecule (known to be important for stabilizing the overall confor-
mation), whereas the absence of this residue in sSLURP-1 may allow Arg20 to protrude from the protein surface, 
possibly allowing it to participate in receptor interactions (Fig. 7B and C). Furthermore, Lys2 and Asp75 form a 
stable salt-bridge, which is absent in rSLURP-1 (Fig. 7C, blue arrow). Such structural changes may account for the 
different biological actions observed for sSLURP-1 and rSLURP-1.
Recently, another member of the Ly6 protein superfamily, SLURP-2, was recombinantly expressed in E. coli 
with an additional N-terminal methionine residue, similar to rSLURP-129. In previous publications utilizing dif-
ferent fusion forms, SLURP-2 was claimed to act selectively on α3-containing nAChRs30. However, rSLURP-2 is 
functionally more similar to ws-Lynx1 than to rSLURP-1. At micromolar concentrations, rSLURP-2 inhibited 
α4β2, α3β2 and α7 nAChRs, whereas at lower concentrations it potentiated the α7 nAChR-mediated currents29. 
This study also provided the NMR structure for rSLURP-2 (PDB ID: 2N99) revealing a considerable confor-
mational mobility, comparable to that earlier observed for rSLURP-1. Although we did not perform a direct 
comparison of the various reported recombinant forms of SLURP-1, our results suggest that even one additional 
methionine residue at the N-terminus, probably by affecting the spatial structure, can produce marked changes 
in the functional activity of Ly6 proteins.
Figure 7. Comparison of the synthetic and recombinant human SLURP-1 structural models. (A) Deletion 
of the methionine (Met0) residue did not significantly alter the overall molecule motility of sSLURP-1 (top). 
For comparison, rSLURP-1 (bottom) is also presented. Seven superimposed frames from molecular dynamics 
simulations are shown. The N-terminal region of interest is boxed and the three protruding fingers are labeled 
I–III. (B) Electrostatic-surface profile of rSLURP-1 (bottom) and sSLURP-1 (top) showing that the positively 
charged Arg20 is now more solvent exposed. Arrows show regions occupied by Met0 residue in rSLURP-1 
or solvent-accessible area in sSLURP-1. (C) Superimposed rSLURP-1 (light brown) and sSLURP-1 (cyan) 
structures showing the differences in the “head” region where Met0 is located in rSLURP-1. The N-terminal 
amino groups are indicated by red arrows. In the sSLURP-1 structure, a salt-bridge between residues Lys2 and 
Asp75 is present (blue arrow). Some residues have been omitted for clarity.
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Conclusions
We wish to emphasize that our work on the synthetic protein identical in amino acid sequence to the 
naturally-occurring human SLURP-1 does not undermine the previous work on Ly6 analogs produced in E. coli. 
The activities reported with them may open new avenues to diagnostics and drug development. However, our 
results clearly show that unraveling physiologically-relevant mechanisms for endogenous regulators requires the 
study of compounds which should be as close as possible to the native proteins. In this context, total chemical syn-
thesis has been particularly instrumental in the past for small proteins, and recent advances in peptide chemistry14,31  
have allowed this concept to be extended to larger proteins. Furthermore, our work highlights the need for strict 
compound characterization standards if results are to be reproducible and transferable. With the advancements 
in modern analytical techniques that are customary in synthetic organic chemistry (high-resolution mass spec-
trometry, NMR and X-ray structure determination) it has become necessary to apply the same rigorous standards 
to proteins and other biologics produced by recombinant expression.
Our study revealed, for the first time, human sSLURP-1 interactions with several neuronal nAChR subtypes 
(hα3β4, hα3β2, hα4β4 and hα9α10). We expect these findings will be important for understanding the in vivo 
function of SLURP-1 in human health and disease in the future.
Methods
Peptide synthesis. All amino acids used were of the L-configuration. The SLURP-1[51–81] 
(CSSSCVATDPDSIGAAHLIFCCFRDLCNSEL) segment was synthesized by automated Fmoc SPPS using stand-
ard protocols. The peptide was assembled on 2-chlorotrityl chloride resin using the following side chain protect-
ing groups: Cys(Trt), Asp(tBu), Glu(tBu), His(Trt), Asn(Trt), Arg(Pbf), Ser(tBu) and Thr(tBu). Resin cleavage 
and side-chain deprotection were carried out by suspending the dried peptide-resin in cleavage cocktail (trif-
luoroacetic acid (TFA):triisopropylsilane: H2O;95:2.5:2.5) (v/v/v)). After stirring for 1.5 h at room temperature, 
majority of the TFA was evaporated under vacuum and the peptide was precipitated with ice-cold diethyl ether. 
The peptide was dissolved in 50% acetonitrile (ACN)/water containing 0.05% TFA and lyophilized. Peptide 
α-thioalkylesters corresponding to SLURP-1[1–20]- α -thioester (LKCYTCKEPMTSASCRTITR-[COS]-Ser) and 
SLURP-1[21–50]-α-thioester (Thz-KPEDTACMTTLVTVEAEYPFNQSPVVTRS-[COS]-Lys) were assembled by 
manual in situ neutralization Boc chemistry as described previously32,33. The following standard side chain pro-
tection groups were used: Cys(4-MeBzl), Arg(Tos), Asp(OcHx), Asn(Xan), Glu(OcHx), Gln(Xan), Lys(2Cl-Z), 
Ser(Bzl), Thr(Bzl), Tyr(Br-Z). Following chain assembly, peptides were side chain-deprotected and simultane-
ously cleaved from the resin by treatment with anhydrous HF containing 10% (v/v) p-cresol for 1 h at 0 °C. HF was 
evaporated under reduced pressure. The crude product was precipitated and washed with chilled diethyl ether, 
then dissolved in 50% (v/v) aqueous ACN containing 0.1% TFA (v/v) and lyophilized. Peptides were purified by 
reversed-phase high-pressure liquid chromatography (RP-HPLC) using a preparative Vydac C18 (22 × 250 mm) 
column on a Shimadzu Prominence platform. Crude peptides were dissolved in a 10% (v/v) ACN-water mixture 
containing 0.05% (v/v) TFA, before being loaded onto the column pre-equilibrated with 10% of solvent B (ACN: 
H2O:TFA; 89.5:10:0.05) in solvent A (H2O:TFA; 99.5:0.05). Peptides were eluted using linear gradients of solvent 
B in solvent A, and fractions were collected across the expected elution time. Peptide purity and identity were 
assessed by ESI-MS on API-2000 mass spectrometer (Applied Biosystems) and by analytical scale uHPLC on a 
Shimadzu Nexera system equipped with an Agilent Zorbax C18 column (1.8 μm, 2.1 × 100 mm). Fractions con-
taining the desired product were pooled, lyophilized and stored at −20 °C.
One-pot native chemical ligation. Initially, 76 mg of SLURP-1[51–81] (MW: 3278.7, 23.2 µmol) and 90 mg of 
SLURP-1[21–50] (MW: 3545.9, 25.4 µmol) were dissolved in 15 mL of ligation buffer (6 M GdmHCl, 200 mM 
Na-phosphate, 50 mM mercaptophenylacetic acid, 40 mM TCEP, pH 7.0). The mixture was stirred under an 
argon atmosphere for 12 h after which LC-MS analysis indicated near quantitative product formation, yielding 
SLURP-1[21–81] (Cys21Thz) with an observed mass 6590.2 ± 0.6 Da, calculated mass: 6590.4 Da (average isotope 
composition).
Methoxyamine HCl was added to a final concentration of 250 mM and the pH was adjusted to 4.0–4.1 with 
concentrated HCl. The reaction was left for 8 h and stirred under an argon atmosphere. The pH was adjusted to 
7.0 by adding 4 M NaOH and 71 mg of SLURP-1[1–20] (MW: 2467.8, 28.8 μmol) were subsequently added. The 
pH was re-adjusted again to 6.9–7.0, and the mixture was stirred at room temperature for 10 h under an argon 
atmosphere. A fresh portion of TCEP (20 mM final concentration) was added and the mixture was stirred for 
another 20 min. The product was then filtered and purified by HPLC on a Phenomenex C18 column (22 × 250, 
5 μm, 300 Å). It yielded 142 mg (16 μmol, 69%) of the fully reduced 81-mer polypeptide (>95% purity).
In vitro protein folding and disulfide formation. For in vitro folding and disulfide bond formation, 25 mg 
(2.8 μmol) of the purified and fully reduced peptide were dissolved in 5 mL of 6 M GdmHCl to give a concen-
tration of 5 mg/mL. Folding was carried out at 4 °C and initiated by rapid 1:40 dilution of the peptide solution 
with folding buffer (100 mM Tris, 2.0 M urea, 0.5 M arginine, 4 mM reduced glutathione, 1 mM oxidized glu-
tathione, adjusted to pH 8.0 at 4 °C with conc. HCl). The reaction was left at 4 °C and stirred for 3 days after 
which the mixture was acidified with TFA to give a pH of ~4, filtered and purified by HPLC on a Zorbax C3 
column (10 × 250, 3 μm, 300 Å). The mass of synthetic SLURP-1 was determined by high-resolution ESI-MS 
on an AB SCIEX 5600 Triple-TOF mass spectrometer equipped with a nanoelectrospray ionization source. 
SLURP-1 observed mass 8837.1 ± 0.1 Da; calculated mass 8837.02 Da (monoisotopic mass). Isolated yield: 
11.4 mg (1.3 μmol, 46%).
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NMR analysis. Synthetic SLURP-1(4 mg) was dissolved in 500 μL of 90% H2O/10% D2O solution and adjusted 
to pH 4.8 by adding 1 M NaOH. 2D 1H-1H TOCSY, NOESY as well as 1H-15N HSQC spectra were collected 
at 310 K using a 600 MHz Bruker spectrometer equipped with a cryogenically cooled probe. All spectra were 
recorded with an interscan delay of 1.0 s. The NOESY and TOCSY mixing times were 200 ms and 80 ms, respec-
tively. Standard Bruker pulse sequences were used with WATERGATE for solvent suppression. NMR data were 
processed using Topspin (Bruker) and analyzed by CCPNMR34.
Molecular modeling. SLURP-1 was modeled by removing the N-terminal methionine residue from the PDB 
2MUO structure using UCSF Chimera35. Both sSLURP-1 and rSLURP-1 structures were subjected to consequent 
equilibration 100 ns NVT (constant number of particles, volume and temperature) and 100 ns NPT (constant 
number of particles, pressure and temperature) ensemble simulations with constrained heavy atoms followed by 
50 ns unconstrained molecular dynamics simulations using the GROMACS-5.0.4 package (reference temperature 
310 K, 100 mM NaCl). Then, three individual frames from each of these two simulations were used as starting 
structures for 5 ns unconstrained molecular dynamics simulations to confirm reproducibility of results.
Electrophysiology. In vitro cRNA synthesis. Plasmid pMXT construct of human nAChR α7 and plasmid 
pSP64 construct of human nAChR α4 were linearized with BamHI, and plasmid pT7TS constructs of human 
nAChR α3, α9, α10, β2, and β4 were linearized with XbaI restriction enzymes (NEB, Ipswich, MA, USA).
Plasmid pcDNA3.1/Hygro(+) construct of rat nAChR α7 was linearized using XbaI, and plasmid pSGEM 
constructs of rat nAChR α9 and α10 were linearized using NheI restriction enzymes (Promega, Madison, WI, 
USA). All linearized plasmid constructs were subjected to in vitro cRNA transcription using SP6 (human nAChR 
α7 and α4) and T7 (human nAChR α3, α9, α10, β2, and β4, and rat nAChR α7, α9 and α10) mMessage mMa-
chine® transcription kits (AMBION, Foster City, CA, USA).
Oocyte preparation and microinjection. Stage V-VI oocytes (Dumont’s classification; 1200–1300 μm in diameter) 
were obtained from Xenopus laevis, defolliculated with 1.5 mg/mL collagenase Type II (Worthington Biochemical 
Corp., Lakewood, NJ, USA) at room temperature (21–24 °C) for 1–2 h in OR-2 solution containing (in mM) 82.5 
NaCl, 2 KCl, 1 MgCl2 and 5 HEPES at pH 7.4. Oocytes were injected with 5 ng of human nAChR α3β2, α3β4, 
α4β2, α4β4 or α7 cRNAs, 35 ng of human nAChR α9α10 cRNA or 9 ng of rat nAChR α7 and α9α10 cRNA 
(concentration confirmed spectrophotometrically and by gel electrophoresis) using glass pipettes pulled from 
glass capillaries (3-000-203 GX, Drummond Scientific Co., Broomall, PA, USA). Oocytes were incubated at 18 °C 
in sterile ND96 solution composed of (in mM) 96 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2 and 5 HEPES at pH 7.4, supple-
mented with 5% fetal bovine serum (FBS), 50 mg/L gentamicin (GIBCO, Grand Island, NY, USA) and 10000 U/mL 
penicillin-streptomycin (GIBCO, Grand Island, NY, USA). All procedures were approved by the University of 
Sydney Animal Ethics Committee and were performed in accordance with the Australian code of practice for the 
care and use of animals for scientific purposes (8th edition, 2013).
Oocyte two-electrode voltage clamp recording and data analysis. Electrophysiological recordings were carried 
out 2–7 days post cRNA microinjection. Two-electrode voltage clamp recording of X. laevis oocytes expressing 
human nAChRs was performed at room temperature (21–24 °C) using a GeneClamp 500B amplifier and pClamp9 
software interface (Molecular Devices, Sunnyvale, CA, USA) at a holding potential −80 mV. For rat nAChRs, 
electrophysiological recordings were made using turbo TEC-03X amplifier (NPI Electronic, Germany) and 
WinWCP recording software (University of Strathclyde, UK), at a holding potential −60 mV. Voltage-recording 
and current-injecting electrodes were pulled from GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston, 
MA, USA) and filled with 3 M KCl, giving resistances of 0.3–1 MΩ.
Oocytes expressing human nAChR α9α10 were incubated with 100 μM BAPTA-AM (Sigma-Aldrich, St. 
Louis, MO, USA) at 18 °C for ~3 h before recording and perfused with ND115 solution containing (in mM): 
115 NaCl, 2.5 KCl, 1.8 CaCl2, and 10 HEPES at pH 7.4. Oocytes expressing rat nAChRs were perfused with Ba2+ 
Ringer’s solution containing (in mM) (115 NaCl, 2.5 KCl, 1.8 BaCl2, 10 HEPES at pH 7.2), whereas other human 
nAChR-expressing oocytes were perfused with ND96 solution. All oocytes were perfused at a rate of 2 mL/min in 
an OPC-1 perfusion chamber of < 20 µL volume (Automate Scientific, Berkeley, CA, USA).
Initially, oocytes were briefly washed with bath solution (ND96/ND115/Ba2+ Ringer’s solution) followed by 
3 applications of ACh using a HPLC injector with a 50 µL sample loop. Washout with bath solution was done for 
3 min between ACh applications. Oocytes were incubated with sSLURP-1 for 5 min with the perfusion system 
turned off, followed by co-application of ACh and sSLURP-1 with flowing bath solution. All sSLURP-1 solutions 
were prepared in ND96/ND115 + 0.1% bovine serum albumin (BSA), except for sSLURP-1 in Ba2+ Ringer’s solu-
tion. Peak current amplitudes before (ACh alone) and after (ACh + sSLURP-1) sSLURP-1 incubation were meas-
ured using Clampfit 10.7 software (Molecular Devices, Sunnyvale, CA, USA) or WinWCP software (University 
of Strathclyde, UK), where the ratio of ACh + sSLURP-1-evoked current amplitude to ACh alone-evoked current 
amplitude was used to assess the activity of sSLURP-1 at nAChRs. All electrophysiological data were pooled 
(n = 3 to 14) and represent means ± standard error of the mean (SEM). Data analysis was performed using 
GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). Data sets were compared using unpaired two-tailed 
Student’s t-test. Differences were regarded statistically significant when p < 0.05. The IC50 was determined from 
concentration-response curve fitted to a non-linear regression function and reported with error of the fit.
Calcium imaging of SLURP-1 interaction with α7 nAChR. Mouse neuroblastoma Neuro2a cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, PanEco, Russia) supplemented with 10% FBS (PAA 
Laboratories, Austria). Cells were sub-cultured 24 h before transfection and were plated at density of 10,000 cells 
per well (black 96-well plate, Corning, USA), followed by Lipofectamine (Invitrogen, USA) -mediated transient 
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co-transfection of hα7 nAChR-pCEP4, fluorescent calcium sensor pCase12-cyto (Evrogen, Russia) and chaper-
one Ric3-pCMV6-XL5 or NACHO TMEM35-pCMV6-XL5 plasmid constructs (OriGene, USA). Mouse muscle 
α1, β1, δ and ε nAChR-pRBG4 plasmid constructs were expressed similarly, but without a chaperone.
Transfected Neuro2a cells were grown at 37 °C in 5% CO2-incubator for 48–72 h, then medium was removed 
and the cells were washed with external buffer containing (in mM) 140 NaCl, 2 CaCl2, 2.8 KCl, 4 MgCl2, 20 
HEPES, 10 glucose at pH 7.4. Cells were pre-incubated with 5 μM sSLURP-1 for 20 min at room temperature 
before agonist addition (ACh or epibatidine (Tocris, UK)). To potentiate α7 nAChR response, PNU120596 
(10 μM) was added to the pre-incubation solution. Cells were excited at 485 nm and emitted fluorescence 
was detected at 535 ± 10 nm, using a multimodal microplate reader Hidex Sense (Hidex, Turku, Finland). 
Fluorescence was recorded every 2 s for 3 min following agonist addition. Responses were measured as peak 
intensity minus basal fluorescence level, and are expressed as a percentage of a maximal response obtained to 
agonist. Data files were analyzed using HidexSence software (Hidex, Turku, Finland) and OriginPro 7.5 software 
(OriginLab, MA, USA, for statistical analysis). Negative controls were run in the presence of 4 μM α-Cbt.
Radioligand assay of sSLURP-1 binding to AChBPs and nAChRs. In competition experiments 
with [125I]-α-Bgt, sSLURP-1 (1–100 μM) was pre-incubated 3 h at room temperature with AChBPs (L. stag-
nalis AChBP or A. californica AChBP at final concentrations of 2.4 nM, and 140 nM, respectively) or nAChRs 
(hα7 nAChR-expressing GH4C1 cells or T. californica electric organ membranes at a final concentration of 
toxin-binding sites of 0.4 nM and 1.25 nM, respectively (measured using [125I]-α-Bgt)), in 50 μL buffer consisting 
of 20 mM Tris-HCl and 1 mg/mL BSA, pH 8.0 (binding buffer).
Radioiodinated α-Bgt was added to a final concentration of 0.2 nM, and the mixture was incubated for 5 min. 
Binding was stopped by rapid filtration on double DE-81 filters (Whatman, Maidstone, UK) pre-soaked in bind-
ing buffer (for AChBPs) or GF/C filters (Whatman, Maidstone, UK) pre-soaked in 0.25% polyethylenimine 
(for GH4C1 cells and T. californica electric organ membranes), unbound radioactivity was removed from the 
filters by washout (3 × 3 mL) with the binding buffer. Non-specific binding was determined in all cases using 3 h 
pre-incubation with 10 μM α-Cbt.
Data availability. All data generated during this study are included in the published article and the supple-
mentary information file.
References
 1. Ploug, M. & Ellis, V. Structure-Function-Relationships in the Receptor for Urokinase-Type Plasminogen-Activator - Comparison to 
Other Members of the Ly-6 Family and Snake-Venom Alpha-Neurotoxins. FEBS Lett. 349, 163–168, https://doi.org/10.1016/0014-
5793(94)00674-1 (1994).
 2. Galat, A., Gross, G., Drevet, P., Sato, A. & Menez, A. Conserved structural determinants in three-fingered protein domains. FEBS J. 
275, 3207–3225, https://doi.org/10.1111/j.1742-4658.2008.06473.x (2008).
 3. Loughner, C. L. et al. Organization, evolution and functions of the human and mouse Ly6/uPAR family genes. Human Genomics 10, 
https://doi.org/10.1186/S40246-016-0074-2 (2016).
 4. Tsetlin, V. I. Three-finger snake neurotoxins and Ly6 proteins targeting nicotinic acetylcholine receptors: pharmacological tools and 
endogenous modulators. Trends Pharmacol. Sci. 36, 109–123, https://doi.org/10.1016/j.tips.2014.11.003 (2015).
 5. Adermann, K. et al. Structural and phylogenetic characterization of human SLURP-1, the first secreted mammalian member of the 
Ly-6/uPAR protein superfamily. Protein Sci. 8, 810–819 (1999).
 6. Grando, S. A. Basic and clinical aspects of non-neuronal acetylcholine: Biological and clinical significance of non-canonical ligands 
of epithelial nicotinic acetylcholine receptors. Journal of Pharmacological Sciences 106, 174–179, https://doi.org/10.1254/jphs.
FM0070087 (2008).
 7. Matsumoto, H. et al. Localization of Acetylcholine-Related Molecules in the Retina: Implication of the Communication from 
Photoreceptor to Retinal Pigment Epithelium. Plos One 7, e42841, https://doi.org/10.1371/journal.pone.0042841 (2012).
 8. Moriwaki, Y. et al. Immune system expression of SLURP-1 and SLURP-2, two endogenous nicotinic acetylcholine receptor ligands. 
Life Sci. 80, 2365–2368, https://doi.org/10.1016/j.lfs.2006.12.028 (2007).
 9. Moriwaki, Y. et al. Primary sensory neuronal expression of SLURP-1, an endogenous nicotinic acetylcholine receptor ligand. 
Neurosci. Res. 64, 403–412, https://doi.org/10.1016/j.neures.2009.04.014 (2009).
 10. Miwa, J. M. et al. lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron 
23, 105–114, https://doi.org/10.1016/S0896-6273(00)80757-6 (1999).
 11. Ibanez-Tallon, I. et al. Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous 
prototoxin lynx1. Neuron 33, 893–903, https://doi.org/10.1016/S0896-6273(02)00632-3 (2002).
 12. Chimienti, F. et al. Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. 
Hum. Mol. Genet. 12, 3017–3024, https://doi.org/10.1093/hmg/ddg320 (2003).
 13. Lyukmanova, E. N. et al. Human Secreted Ly-6/uPAR Related Protein-1 (SLURP-1) Is a Selective Allosteric Antagonist of alpha 7 
Nicotinic Acetylcholine Receptor. Plos One 11, e0149733, https://doi.org/10.1371/journal.pone.0149733 (2016).
 14. Dawson, P. E., Muir, T. W., Clark-Lewis, I. & Kent, S. B. Synthesis of proteins by native chemical ligation. Science 266, 776–779 
(1994).
 15. Dawson, P. E. & Kent, S. B. H. Synthesis of native proteins by chemical ligation. Annu. Rev. Biochem. 69, 923–960 (2000).
 16. Bang, D. & Kent, S. B. A one-pot total synthesis of crambin. Angew. Chem. Int. Ed. 43, 2534–2538 (2004).
 17. Villain, M., Vizzavona, J. & Rose, K. Covalent capture: a new tool for the purification of synthetic and recombinant polypeptides. 
Chem. Biol. 8, 673–679 (2001).
 18. Schroeder, C. I. et al. Chemical Synthesis, 3D Structure, and ASIC Binding Site of the Toxin Mambalgin-2. Angew. Chem. Int. Ed. 53, 
1017–1020, https://doi.org/10.1002/Anie.201308898 (2014).
 19. Shulepko, M. A. et al. Human neuromodulator SLURP-1: Bacterial expression, binding to muscle-type nicotinic acetylcholine 
receptor, secondary structure, and conformational heterogeneity in solution. Biochemistry-Moscow 78, 204–211, https://doi.
org/10.1134/S0006297913020090 (2013).
 20. Hurst, R. S. et al. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo 
characterization. J. Neurosci. 25, 4396–4405, https://doi.org/10.1523/JNEUROSCI.5269-04.2005 (2005).
 21. Horiguchi, K. et al. Expression of SLURP-1, an Endogenous alpha 7 Nicotinic Acetylcholine Receptor Allosteric Ligand, in Murine 
Bronchial Epithelial Cells. J. Neurosci. Res. 87, 2740–2747, https://doi.org/10.1002/jnr.22102 (2009).
 22. Pettersson, A., Nylund, G., Khorram-Manesh, A., Nordgren, S. & Delbro, D. S. Nicotine induced modulation of SLURP-1 expression 
in human colon cancer cells. Autonomic Neuroscience 148, 97–100, https://doi.org/10.1016/j.autneu.2009.03.002 (2009).
www.nature.com/scientificreports/
1 1Scientific REPoRTS | 7: 16606  | DOI:10.1038/s41598-017-16809-0
 23. Lyukmanova, E. N. et al. NMR Structure and Action on Nicotinic Acetylcholine Receptors of Water-soluble Domain of Human 
LYNX1. J. Biol. Chem. 286, 10618–10627, https://doi.org/10.1074/jbc.M110.189100 (2011).
 24. Lyukmanova, E. N. et al. Water-soluble LYNX1 Residues Important for Interaction with Muscle-type and/or Neuronal Nicotinic 
Receptors. J. Biol. Chem. 288, 15888–15899, https://doi.org/10.1074/jbc.M112.436576 (2013).
 25. Mourier, G., Dutertre, E., Fruchart-Gaillard, C., Menez, A. & Servent, D. Chemical synthesis of MT1 and MT7 muscarinic toxins: 
Critical role of arg-34 in their interaction with M-1 muscarinic receptor. Mol. Pharmacol. 63, 26–35, https://doi.org/10.1124/
Mol.63.1.26 (2003).
 26. Poh, S. L. et al. A synthetic weak neurotoxin binds with low affinity to Torpedo and chicken alpha 7 nicotinic acetylcholine receptors. 
Eur. J. Biochem. 269, 4247–4256, https://doi.org/10.1046/j.1432-1033.2002.03113.x (2002).
 27. Jin, A. H. et al. MrIC, a Novel alpha-Conotoxin Agonist in the Presence of PNU at Endogenous alpha 7 Nicotinic Acetylcholine 
Receptors. Biochemistry 53, 1–3, https://doi.org/10.1021/bi400882s (2014).
 28. Kasheverov, I. E. et al. 6-Bromohypaphorine from Marine Nudibranch Mollusk Hermissenda crassicornis is an Agonist of Human 
alpha 7 Nicotinic Acetylcholine Receptor. Mar. Drugs 13, 1255–1266, https://doi.org/10.3390/md13031255 (2015).
 29. Lyukmanova, E. N. et al. Secreted Isoform of Human Lynx1 (SLURP-2): Spatial Structure and Pharmacology of Interactions with 
Different Types of Acetylcholine Receptors. Scientific Reports 6, https://doi.org/10.1038/Srep30698 (2016).
 30. Arredondo, J., Chernyavsky, A. I., Jolkovsky, D. L., Webber, R. J. & Grando, S. A. SLURP-2: A novel cholinergic signaling peptide in 
human mucocutaneous epithelium. J. Cell. Physiol. 208, 238–245, https://doi.org/10.1002/jcp.20661 (2006).
 31. Bondalapati, S., Jbara, M. & Brik, A. Expanding the chemical toolbox for the synthesis of large and uniquely modified proteins. Nat. 
Chem. 8, 407–418, https://doi.org/10.1038/Nchem.2476 (2016).
 32. Hackeng, T. M., Griffin, J. H. & Dawson, P. E. Protein synthesis by native chemical ligation: Expanded scope by using straightforward 
methodology. Proc. Natl. Acad. Sci. USA 96, 10068–10073 (1999).
 33. Schnölzer, M., Alewood, P., Jones, A., Alewood, D. & Kent, S. B. In situ neutralization in Boc-chemistry solid phase peptide synthesis. 
Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 40, 180–193 (1992).
 34. Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: Development of a software pipeline. Proteins: Struct., Funct., 
Bioinf. 59, 687–696, https://doi.org/10.1002/Prot.20449 (2005).
 35. Pettersen, E. F. et al. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612, 
https://doi.org/10.1002/jcc.20084 (2004).
Acknowledgements
The authors are grateful to Prof. A. Arseniev and Dr. Z. Shenkarev for providing NMR chemical shifts for 
recombinant SLURP-1. We are also grateful to Prof. A.B. Smit (VU University, Amsterdam, the Netherlands) for 
AChBPs; to Eli Lilly (London) for GH4C1 cells transfected with the human α7 nAChR; to Prof F. Hucho (Free 
University of Berlin, Germany) for preparation of membranes from the T. californica electric organ. The authors 
appreciate fruitful discussions with Prof. M. Hollmann and Dr. C. Methfessel (Department of Biochemistry I, 
Ruhr University Bochum, Germany). D.J.C. is an Australian Research Council Laureate Fellow (FL150100146). 
VIT, ENS, DSK and IEK were supported by RSF grant № 16-14-00215; P.-J.C., GF and IVS were supported by 
RFBR-CNRS grant 14-04-91051; and DJA was supported by an Australian Research Council Discovery Project 
Grant (DP150103990).
Author Contributions
T.D. and P.T. designed and performed the synthesis of SLURP-1, and T.D. performed NMR spectroscopy and 
data evaluation. I.V.S. and E.N.S. performed Ca2+ imaging experiments. H.S.T., E.N.S. and D.S.K. conducted 
electrophysiological experiments. D.S.K. performed molecular modelling. I.E.K. and G.F. prepared AChBPs 
and performed radioligand binding assay. T.D., H.S.T. and V.I.T. wrote the manuscript. P.J.C., D.J.C. and D.J.A. 
coordinated the work and edited the manuscript. V.I.T. designed the project and edited the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-16809-0.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
